Knight Therapeutics Inc. (TSX:GUD)
Canada
· Delayed Price · Currency is CAD 6.09
+0.09 (1.50%)
Mar 28, 2025, 4:00 PM EST
Knight Therapeutics Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 371.3 | 328.2 | 293.56 | 243.48 | 199.52 | Upgrade
|
| Revenue Growth (YoY) | 13.13% | 11.80% | 20.57% | 22.03% | 320.38% | Upgrade
|
| Cost of Revenue | 196.9 | 175.55 | 155.5 | 128.07 | 117.83 | Upgrade
|
| Gross Profit | 174.41 | 152.65 | 138.06 | 115.41 | 81.69 | Upgrade
|
| Selling, General & Admin | 99.35 | 83.69 | 88.62 | 74.38 | 70.74 | Upgrade
|
| Research & Development | 23.3 | 17.55 | 14.76 | 12.69 | 11.73 | Upgrade
|
| Operating Expenses | 167.01 | 146.28 | 155.12 | 128.24 | 108 | Upgrade
|
| Operating Income | 7.4 | 6.37 | -17.06 | -12.83 | -26.31 | Upgrade
|
| Interest Expense | -9.22 | -12.49 | -6.6 | -3.62 | -3.4 | Upgrade
|
| Interest & Investment Income | 10.41 | 12.58 | 10.63 | 7.38 | 14.32 | Upgrade
|
| Currency Exchange Gain (Loss) | -4.19 | -15.17 | 7.44 | -3.74 | -14.16 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.23 | 12.3 | -22.68 | 19.07 | 60.3 | Upgrade
|
| EBT Excluding Unusual Items | 4.62 | 3.58 | -28.27 | 6.27 | 30.76 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -3.69 | Upgrade
|
| Gain (Loss) on Sale of Investments | -11.79 | -19.62 | - | - | 4.17 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 2.95 | Upgrade
|
| Asset Writedown | - | -9.26 | -23.98 | - | -0.66 | Upgrade
|
| Other Unusual Items | 9.23 | 3.3 | 8.29 | 0.42 | -1.44 | Upgrade
|
| Pretax Income | 2.05 | -21.99 | -43.96 | 6.69 | 32.09 | Upgrade
|
| Income Tax Expense | -2.28 | -5.15 | -14.07 | -8.99 | 0.33 | Upgrade
|
| Earnings From Continuing Operations | 4.33 | -16.84 | -29.89 | 15.68 | 31.76 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | 10.31 | Upgrade
|
| Net Income | 4.33 | -16.84 | -29.89 | 15.68 | 42.07 | Upgrade
|
| Net Income to Common | 4.33 | -16.84 | -29.89 | 15.68 | 42.07 | Upgrade
|
| Net Income Growth | - | - | - | -62.74% | 189.78% | Upgrade
|
| Shares Outstanding (Basic) | 101 | 107 | 115 | 124 | 132 | Upgrade
|
| Shares Outstanding (Diluted) | 101 | 107 | 115 | 125 | 132 | Upgrade
|
| Shares Change (YoY) | -5.61% | -6.46% | -7.74% | -5.66% | -5.82% | Upgrade
|
| EPS (Basic) | 0.04 | -0.16 | -0.26 | 0.13 | 0.32 | Upgrade
|
| EPS (Diluted) | 0.04 | -0.16 | -0.26 | 0.13 | 0.32 | Upgrade
|
| EPS Growth | - | - | - | -60.55% | 219.21% | Upgrade
|
| Free Cash Flow | 33.81 | 34.99 | 42.12 | 40.79 | -17.58 | Upgrade
|
| Free Cash Flow Per Share | 0.33 | 0.33 | 0.37 | 0.33 | -0.13 | Upgrade
|
| Gross Margin | 46.97% | 46.51% | 47.03% | 47.40% | 40.94% | Upgrade
|
| Operating Margin | 1.99% | 1.94% | -5.81% | -5.27% | -13.18% | Upgrade
|
| Profit Margin | 1.17% | -5.13% | -10.18% | 6.44% | 21.08% | Upgrade
|
| Free Cash Flow Margin | 9.11% | 10.66% | 14.35% | 16.75% | -8.81% | Upgrade
|
| EBITDA | 55.96 | 53.26 | 40.98 | 32.46 | 2.97 | Upgrade
|
| EBITDA Margin | 15.07% | 16.23% | 13.96% | 13.33% | 1.49% | Upgrade
|
| D&A For EBITDA | 48.56 | 46.89 | 58.04 | 45.29 | 29.28 | Upgrade
|
| EBIT | 7.4 | 6.37 | -17.06 | -12.83 | -26.31 | Upgrade
|
| EBIT Margin | 1.99% | 1.94% | -5.81% | -5.27% | -13.18% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 1.01% | Upgrade
|
Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.